Amryt On Targeting Rare Disease Space In The Middle East
Executive Summary
The rare and orphan drug company Amryt speaks to the Pink Sheet about how to do business in the Middle East and why seeking marketing authorization could be a better long-term strategy than catering for named patient requests.
You may also be interested in...
Middle East And North Africa Dip Toes In HTA And Access Agreements
Saudi Arabia is set to introduce a new pricing policy that will affect the rest of the region.
How Middle Eastern Markets Are Transforming Drug Reviews And Driving Competitiveness
The UAE, Jordan, Egypt and Saudi Arabia have all recently announced or implemented new verification/abridged regulatory pathways to improve access to medicines and free up resources.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.